12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Japan Tobacco, Torii sales and marketing update

Japan Tobacco granted its Torii pharmaceutical subsidiary exclusive rights to commercialize a single-tablet of Japan Tobacco's elvitegravir plus cobicistat/emtricitabine/tenofovir in Japan to treat HIV infection. Japan Tobacco will receive from Torii an upfront payment of ¥2.7 billion ($34.3 million).

Japan Tobacco plans to submit an NDA...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >